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ABSTRACT 
Dissolution testing is a critical methodology which is widely utilized in the development of a new pharmaceutical product. The test, 
in its simplest form, consists of placing the formulation in a dissolution apparatus containing suitable dissolution medium, allowing 
it to dissolve over a specified period of time and then assaying the resultant solution using appropriate analytical method to 
determine the amount of drug. Dissolution tests are relevant for an array of investigations like drug degradation profiles, stability and 
shelf life studies, physical and mechanical testing of dosage forms, incoming QC testing on raw materials etc. The present review 
outlines the recent findings on various dissolution apparatuses, their modifications, methods for degassing of media like Helium 
sparging, Heating and filtering, Vacuum degassing, sonication and dissolution testing of various dosage forms like Immediate 
Release (IR) Dosage forms, Delayed Release Dosage Forms, Extended Release Dosage Forms, Transdermal Delivery Systems, 
Powders, Chewable Tablets, Buccal Tablets, Chewing Gums, Soft Gelatin Capsule , Aerosols, Suppositories and other Semisolids.  
Keywords: Dissolution, Factor affecting dissolution, Dissolution apparatus 
________________________________________________________________________________________________ 
 
1. INTRODUCTION 
Most medicinal drugs are formulated into tablets, 
capsules or other forms of medicine.  Formulating a 
medicine means mixing the medicinal drug with other 
ingredients (called excipients) according to a prescribed 
recipe (the formulation). These ingredients have a 
number of purposes in a tablet, for example, they might 
help bind the tablet together, control the rate of release 
of the drug and improve the taste of the tablet.  
Dissolution of a tablet involves its disintegration into 
smaller and smaller particles from which the medicinal 
drug is released more and more rapidly. The speed at 
which a medicinal drug is released from a tablet or 
capsule and dissolves in solutions that mimic fluids in 
the GI tract is an increasingly important measurement. 
Knowledge of this rate of dissolution contributes to the 
formulation, development and regulatory approval of 
medicines. 
1
 It is also important for quality control, 
checking that the tablets from a production run have the 
required characteristics. The process of dissolution 
followed by absorption determines, in part, the 
bioavailability of the drug. The rate of dissolution can be 
determined in vivo by taking samples of a person’s 
plasma or urine and measuring the drug concentration in 
them. However, this is not appropriate for routine 
measurements on the vast numbers of compounds 
investigated during drug discovery and development. 
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Instead, in vitro tests are used. Fluids in the body are 
simulated and dissolution experiments carried out in 
laboratory glassware. Conditions for these tests are 
carefully defined. 
1,2 ,3
,
4,5
 
Dissolution of a tablet depends on 
2 
 
 The size of the granules of medicinal drug;  
 The structure of the tablets and the nature of the 
excipients used in the formulation;  
 The pH of fluids in the GI tract.  
 It also depends on temperature, but since body 
temperature is always 37 °C (or very close) 
temperature is not a factor in this situation. 
2. Importance of dissolution 
1, 2,5
 
Results from in-vitro dissolution rate experiments can be 
used to explain the observed differences in in-vivo 
availability. 
 Dissolution testing provides the means to evaluate 
critical parameters such as adequate bioavailability 
and provides information necessary to formulator in 
development of more efficacious and 
therapeutically optimal dosage forms.  
 Most sensitive and reliable predictors of in-vivo 
availability.  
 Dissolution analysis of pharmaceutical dosage 
forms has emerged as single most important test that 
will ensure quality of product.  
 It can ensure bioavailability of product between 
batches that meet dissolution criteria.  
 Ensure batch-to-batch quality equivalence both in-
vitro and in-vivo, but also to screen formulations 
during product development to arrive at optimally 
effective products.  
 Physicochemical properties of model can be 
understood needed to mimic in-vivo environment.  
 Such models can be used to screen potential drug 
and their associated formulations for dissolution and 
absorption characteristics.  
 Serve as quality control procedures, once the form 
of drug and its formulation have been finalized.  
3. Application of Dissolution 
  
 
 
Figure 1: application of dissolution  
 
3.1. Product development 
1,2, 5,7,8
 
 Important tool during development of dosage form.  
 Aids in guiding the selection of prototype 
formulations and for determining optimum levels of 
ingredients to achieve drug release profiles, 
particularly for extended release formulations.  
 Also guides in selection of a “market-image” 
product to be used in pivotal in-vivo bioavailability 
or bioequivalence studies.  
3.2. Quality assurance
 8
  
D.T. performed on future production lots and is used to 
assess the lot-to-lot performance characteristics of drug 
product and provide continued assurance of product 
integrity/similarity.  
3.3. Product stability 
In-vitro dissolution also used to assess drug product 
quality with respect to stability and shelf-life. As product 
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age, physicochemical changes to the dosage form may 
alter dissolution characteristics of drug product over 
time. For some products, polymorph transformations to 
more stable, and hence less soluble crystalline forms 
may result in reduced dissolution rates.
8
 
3.4. Comparability assessment  
Also useful for assessing the impact of pre- or post- 
approval changes to drug product such as changes to 
formulation or manufacturing process. Thus, in-vitro 
comparability assessment is critical to ensure continued 
performance equivalency and product similarity.
8
 
3.5. Waivers of in-vivo bioequivalence requirements  
In-vitro dissolution testing or drug release testing may 
be used for seeking waiver of required product to 
conduct in-vivo bioavailability or bioequivalence 
studies. 
8
 
4. Factor affecting dissolution rate 
1.7,8
 
 Physicochemical Properties of Drug  
 Drug Product Formulation Factors  
 Processing Factors  
 Factors Relating Dissolution Apparatus  
 Factors Relating Dissolution Test Parameters  
4.1. Physicochemical properties of drug 
2,8,9
 
4.1.1. Drug solubility  
Solubility of drug plays a prime role in controlling its 
dissolution from dosage form. Aqueous solubility of 
drug is a major factor that determines its dissolution rate. 
Minimum aqueous solubility of 1% is required to avoid 
potential solubility limited absorption problems.  Studies 
of 45 compound of different chemical classes and a wide 
range of solubility revealed that initial dissolution rate of 
these substances is directly proportional to their 
respective solubility. 
2
 
4.1.2. Salt formation  
 It is one of the common approaches used to increase 
drug solubility and dissolution rate. It has always been 
assumed that sodium salts dissolve faster than their 
corresponding insoluble acids. Eg. sodium and 
potassium salts of Peniciilin G, sulfa drugs, phenytoin, 
barbiturates etc. While in case of Phenobarbital 
dissolution of sodium salt was slower than that of weak 
acid. Same is the case for weak base drug, strong acid 
salts, such as hydrochlorides and sulphates of weak 
bases such as epinephrine, tetracycline are commonly 
used due to high solubility. However, free bases of 
chlortetracycline, methacycline were more soluble than 
corresponding hydrochloride salt at gastric pH values, 
due to common ion suppression.
7
 
4.1.3. Particle size  
There is a direct relationship between surface area of 
drug and its dissolution rate. Since, surface area 
increases with decrease in particle size, higher 
dissolution rates may be achieved through reduction of 
particle size. Micronization of sparingly soluble drug to 
reduce particle size is by no means a guarantee of better 
dissolution and bioavailability. Micronization of 
hydrophobic powders can lead to aggregation and 
floatation when powder is dispersed into dissolution 
medium. So, mere increase in S.A. of drug does not 
always guarantee an equivalent increase in dissolution 
rate. Rather, it is increase in the “effective” S.A., or area 
exposed to dissolution medium and not the absolute S.A. 
that is directly proportional to dissolution 
rate.Hydrophobic drugs like phenacetin, aspirin shows 
decrease in dissolution rate as they tend to adsorb air at 
the surface and inhibit their wettability. Problem 
eliminated by evacuating surface from adsorbed air or 
by use of surfactants. So these drugs in-vivo exhibit 
excellent wetting due to presence of natural surfactants 
such as bile salts. 
1,2, 8
  
4.1.4. Solid state characteristics  
Solid phase characteristics of drug, such as amorphicity, 
crystallinity, state of hydration and polymorphic 
structures have significant influence on dissolution rate. 
Anhydrous forms dissolve faster than hydrated form bcz 
they are thermodynamically more active than hydrates. 
Eg. Ampicillin anhydrate faster dissolution rate than 
trihydrate. Amorphous forms of drug tend to dissolve 
faster than crystalline materials. E.g. Novobiocin 
suspension, Griseofulvin.
9,10
 
4.1.5. Co-precipitation  
Dissolution rate of sulfathiazole could be significantly 
increased by co-precipitating the drug with povidone. 
8
 
4.2. Drug Product Formulation Factors  
Dissolution rate of pure drug can be altered significantly 
when mixed with various adjuncts during manufacturing 
process such as diluents, dyes, binders, granulating 
agents, disintegrants and lubricants. Generically 
identical tablet or capsules exhibited differences in their 
dissolution rates of their active ingredients.
5,10
 
4.2.1. Diluents   
Diluents in capsule & tablet influence the dissolution 
rate of drug. Studies of starch on dissolution rate of 
salicylic acid tablet by dry double compression process 
shows three times increase in dissolution rate when the 
starch content increases from the 5 – 20 %. Here starch 
particles form a layer on the outer surface of 
hydrophobic drug particles resulting in imparting 
hydrophilic character to granules & thus increase in 
effective surface area & rate of dissolution.  Different 
types of dissolution apparatus utilized affect ranking of 
different varieties of starch. With stirring type of 
agitation, order was potato starch > cornstarch > 
arrowroot starch > rice starch. With oscillating type, a 
different order observed. Corn > rice > arrowroot > 
potato.The dissolution rate is not only affected by nature 
of the diluent but also affected by excipient dilution 
2
 
4.2.2. Disintegrants  
Disintegrating agent added before & after the 
granulation affects the dissolution rate. Studies of 
various disintegrating agents on Phenobarbital tablet 
showed that when copagel (low viscosity grade of Na 
CMC) added before granulation decreased dissolution 
rate but if added after did not had any effect on 
dissolution rate. Microcrystalline cellulose is a very 
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good disintegrating agent but at high compression force, 
it may retard drug dissolution. Starch is not only an 
excellent diluent but also superior disintegrant due to its 
hydrophilicity and swelling property. Disintegration and 
dissolution rate of disintegrants with moderate swelling 
capacity depend to a large extent on mixing time of 
drug/excipient preblende. With lubricant. On other hand, 
disintegrants with strong swelling capacity such as 
sodium starch glycolate were hardly affected by mixing 
time with lubricant. 
2,10, 11, 12, 13
 
4.2.3. Binders and Granulating agents  
The hydrophilic binder increase dissolution rate of 
poorly wet table drug. Large amt. of binder increase 
hardness & decrease disintegration /dissolution rate of 
tablet. Non aqueous binders such as ethyl cellulose also 
retard the drug dissolution Phenobarbital tablet 
granulated with gelatin solution provide a faster 
dissolution rate in human gastric juice than those 
prepared using NaCMC or polyethylene glycol 6000 as 
binder.  Gelatin imparted hydrophilic character to 
hydrophobic drug surface whereas PEG 6000 formed a 
poorly soluble complex while NA-CMC was converted 
to its less soluble acid form at the low pH of gastric 
fluid. 
2,8
 
4.2.4. Lubricants  
Lubricants are hydrophobic in nature (metallic stearates) 
and prolong tablet disintegration time by forming water 
repellant coat around individual granules. This retarding 
effect is most imp factor in influencing rate of 
dissolution of solid dosage forms.  Both amount and 
method of addition affect the property. It should be 
added in small amount (1% or less) and should be 
tumbled or mixed gently for only very short time. 
Prolonged mixing the dissolution time. However, if an 
enhancing effect in dissolution of hydrophobic granules 
is desired, water soluble lubricant such as SLS or 
CARBOWAXES may be used. 
8
 
4.2.5. Surfactants  
They enhance the dissolution rate of poorly soluble drug. 
This is due to lowering of interfacial tension, increasing 
effective surface area, which in turn results in faster 
dissolution rate.  E.g Non-ionic surfactant Polysorbate 
80 increase dissolution rate of phenacetin granules. The 
increase was more pronounced when the surfactant was 
sprayed on granules than when it was dissolved in 
granulating agent.  
4.2.6. Water-soluble dyes 
Dissolution rate of single crystal of sulphathiazole was 
found to decrease significantly in presence of FD&C 
Blue No.1. The inhibiting effect was related to 
preferential adsorption of dye molecules on primary 
dissolution sources of crystal surfaces. They inhibit the 
micellar solubilization effect of bile salts on drug. 
Cationic dyes are more reactive in lower conc. than are 
anionic dyes. 
3
 
4.2.7 Coating polymers-  
Tablets with MC coating were found to exhibit lower 
dissoln profiles than those coated with HPMC at 37ºC. 
The differences are attributed to thermal gelation of MC 
at temp near 37º, which creates a barrier to dissoln 
process & essentially changes the dissoln medium. This 
mechanism is substantiated by the fact that at temp 
below the gel point & at increased agitation, the effect 
disappears. 
10
 
4.3. Factors relating dissolution apparatus 
4.3.1 Agitation  
Relationship between intensity of agitation and rate of 
dissolution varies considerably acc. to type of agitation 
used, the degree of laminar and turbulent flow in system, 
the shape and design of stirrer and physicochemical 
properties of solid. Speed of agitation generates a flow 
that continuously changes the liq/solid interface between 
solvent and drug. In order to prevent turbulence and 
sustain a reproducible laminar flow, which is essential 
for obtaining reliable results, agitation should be 
maintained at a relatively low rate. Thus, in general 
relatively low agitation should be applied. 
13
 
I. Basket method- 100 rpm  
II. Paddle method- 50-75 rpm  
4.4. Factors relating dissolution test parameters  
Temperature 
Drug solubility is temperature dependent, therefore 
careful temperature control during dissolution process is 
extremely important. Generally, a temp of 37º ± 0.5 is 
maintained during dissolution determination of oral 
dosage forms and suppositories. However, for topical 
preparations temp as low as 30º and 25º have been used 
2,8,
 
4.5. Dissolution medium  
It is very imp factor affecting dissolution and is itself 
affected by number of factors such as: 
 pH  
 Volume of dissolution medium 
5. Official dissolution monographs 
According to I.P. & E.P. USP for solid dosage forms 
(tablets and capsules) dissolution apparatus used are:  
 Apparatus I –BASKET APPARATUS  
 Apparatus II – BASKET APPARATUS  
According to B.P. apparatus used are:  
 Apparatus I – BASKET APPARATUS  
 Apparatus II – PADDLE APPARATUS  
 Apparatus III – FLOW THROUGH CELL 
APPARATUS
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Appratus-1  
 
Figure 1: Appratus. 1 
1. Temp. - 37±0.5oC  
2. PH - ±0.05 unit in specified monograph  
3. Capacity – 1000 ml  
4. Distance between inside bottom of vessel and 
paddle/basket is maintained at 25±2 mm.  
5. For enteric coated dosage form it is first dissolved in 
0.1 N HCl & then in buffer of pH 6.8 to measure drug 
release. (Limit – NMT 10% of drug should dissolve in 
the acid after 2hr.and about 75% of it should dissolve in 
the buffer after 45 min 
8
 
 
Figure 2: Type 1 Basket 
Advantage- 
Drug products tested 
 Solid dosage  
 Forms Floating 
 Disintegrating and non-disintegratingSingle units 
(e.g. tablets) 
 Multiple units (encapsulated beads) 
 pH change by media addition or replacement. 
Disadvantages 
 Formulation may clog the screen 
 Small disintegrated particles fall out 
2) Apparatus-II - Paddle Apparatus. 
2,8,10
 
 The dosage unit is allowed to sink to the bottom of 
the vessel before rotation of the blade is started.  
 A small, loose piece of no reactive material such as 
not more than a few turns of wire helix may be 
attached to dosage units that would otherwise float.  
 Other validated sinker devices may be used.  
 
 
 
 
Figure 3:  Apparatus. ii. 
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Useful for: Tablets, Capsules, Beads, Delayed release, 
enteric coated dosage forms Standard volume: 
900/1000 ml Advantages 
 Easy to use  
 Robust  
 Can be easily adapted to apparatus 5  
 long experience  
 pH change possible  
 Can be easily automated which is important for 
routine investigations.  
Disadvantages  
 pH/media change is often difficult  
 Hydrodynamics are complex, they vary with site of 
the dosage form in the vessel (sticking, floating) 
and therefore may significantly affect drug 
dissolution  
 Coning.  
 
 
 
Figure 4: Sinkers for floating dosage forms 
Limitations of USP Apparatus 1and 2 
9
 
 USP2 (and USP1) Apparatus has plenty of 
HYDRODYNAMICS.  
 Complicated 3-dimensional flow generated by the 
paddle.  
 Significant impact of convective transport –
Conditions used (50 – 100 rpm) highly exaggerates 
flow in the GI.  
 If Static-tank model used – sink conditions 
artificially generated to simulate sink in GI.  
 Use of solvents and surfactants non-native to GI.  
3) Apparatus III – Reciprocating cylinder 2,7,8,9,10 
he assembly consists of a set of cylindrical, flat-
bottomed glass vessels; a set of glass reciprocating 
cylinders; stainless steel fittings (type 316 or equivalent) 
and screens that are made of suitable nonsorbing and 
nonreactive material(polypropelene) and that are 
designed to fit the tops and bottoms of the reciprocating 
cylinders; and a motor and drive assembly to reciprocate 
the cylinders vertically inside the vessels. The vessels 
are partially immersed in a suitable water bath of any 
convenient size that permits holding the temperature at 
37 ± 0.5 during the test. The dosage unit is placed in 
reciprocating cylinder & the cylinder is allowed to move 
in upward and downward direction constantly. Release 
of drug into solvent within the cylinder measured.  
Useful for: Tablets, Beads, controlled release 
formulations  
Standard volume: 200-250 ml/station  
Advantages:  
 Easy to change the pH-profiles 
 Hydrodynamics can be directly influenced by 
varying the dip rate. 
 Disadvantages: 
 small volume (max. 250 ml) 
 Little experience  
 Limited data 
 
 
 
Figure 5: Apparatus iii 
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4) Apparatus IV – flow through cell 8 11 
 The assembly consists of a reservoir and a pump for 
the Dissolution Medium; a flow-through cell; a 
water bath that maintains the Dissolution Medium at 
37 ± 0.5  
 The cell size is specified in the individual 
monograph.  
 The pump forces the Dissolution Medium upwards 
through the flow-through cell.  
 Place the glass beads into the cell specified in the 
monograph.  
 Place 1 dosage unit on top of the beads or, if 
specified in the monograph, on a wire carrier.  
 Assemble the filter head, and fix the parts together 
by means of a suitable clamping device.  
 Introduce by the pump the Dissolution Medium 
warmed to 37 ± 0.5 through the bottom of the cell 
to obtain the flow rate specified in the individual 
monograph.  
 Collect the elute by fractions at each of the times 
stated.  
 Perform the analysis as directed in the individual 
monograph. 
  
 
  
Figure 6: Apparatus iv 
 
Useful for: Low solubility drugs, Micro particulates, 
Implants, Suppositories, Controlled release formulations 
Variations:  
(A) Open system  
(B) Closed system 
Advantages:  
 Easy to change media pH  
 PH-profile possible  
 Sink conditions  
Disadvantages:  
 Desecration necessary  
 High volumes of media  
 Labor intensive  
5) Apparatus V – Paddle over disk 2.5.6.8 
 Use the paddle and vessel assembly from Apparatus 
2 with the addition of a stainless steel disk assembly 
designed for holding the transdermal system at the 
bottom of the vessel.  
 Other appropriate devices may be used, provided 
they do not sorb, react with, or interfere with the 
specimen being tested  
 The disk assembly for holding the transdermal 
system is designed to minimize any “dead” volume 
between the disk assembly and the bottom of the 
vessel.  
 The disk assembly holds the system flat and is 
positioned such that the release surface is parallel 
with the bottom of the paddle blade  
 The vessel may be covered during the test to 
minimize evaporation.  
Useful for: Transdermal patches Standard volume: 900 
ml  
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Disadvantages:  
 Disk assemmbly restricts the patch size. 
 Borosilicate Glass  
 17 mesh is standard (others available) 
 
 
Figure 7: Apparatus V. Paddle over disk 
 
6) Apparatus VI – cylinder 8 
 Use the vessel assembly from Apparatus 1 except to 
replace the basket and shaft with a stainless steel 
cylinder stirring element and to maintain the 
temperature at 32 ± 0.5 during the test.  
 The dosage unit is placed on the cylinder at the 
beginning of each test, to the exterior of the 
cylinder such that the long axis of the system fits 
around the circumference of the cylinder & removes 
trapped air bubbles.  
 Place the cylinder in the apparatus, and immediately 
rotate at the rate specified in the individual 
monograph.  
7) Apparatus VII – reciprocating holder 8 
 The assembly consists of a set of volumetrically 
calibrated solution containers made of glass or other 
suitable inert material, a motor and drive assembly 
to reciprocate the system vertically and a set of 
suitable sample holders.  
 The solution containers are partially immersed in a 
suitable water bath of any convenient size that 
permits maintaining the temperature, inside the 
containers at 32 ± 0.5  
 For Coated tablet drug delivery system attach each 
system to be tested to a suitable sample holder (e.g., 
by gluing system edge with 2-cyano acrylate glue 
onto the end of a plastic rod or by placing the 
system into a small nylon net bag at the end of a 
plastic rod or within a metal coil attached to a metal 
rod).  
 For Transdermal drug delivery system attach the 
system to a suitable sized sample holder with a 
suitable O-ring such that the back of the system is 
adjacent to and centered on the bottom of the disk-
shaped sample holder or centered around the 
circumference of the cylindrical-shaped sample 
holder. Trim the excess substrate with a sharp 
blade.  
 For Other drug delivery systems attach each system 
to be tested to a suitable holder as described in the 
individual monograph.  
 Suspend each sample holder from a vertically 
reciprocating shaker such that each system is 
continuously immersed in an accurately measured 
volume of Dissolution Medium within a calibrated 
container.  
 Reciprocate at a frequency of about 30 cycles per 
minute with amplitude of about 2 cm, or as 
specified in the individual monograph, for the 
specified time in the medium specified for each 
time point.  
 Perform the analysis as directed in the individual 
monograph.  
 
 
Figure 8: Apparatus VII – reciprocating holder 
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CONCLUSION 
At the conclusion of acceptable installation and 
operational qualifications, the dissolution apparatus is 
considered validated and acceptable for use to perform 
dissolution testing. The system suitability tests should 
be performed after any significant equipment change 
(e.g., a change from a basket apparatus to a paddle 
apparatus, unless multiple apparatus are qualified at the 
time of validation) or relocation of the dissolution 
apparatus (e.g., to another laboratory). Barring any 
significant change, the system suitability tests should be 
conducted at least twice a year as part of a robust 
preventive maintenance program. 
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